Dr. Sarah Wood and Kimberley Desir's presentation to the RWPC's Positive Committee on Children's Hospital of Philadelphia's PrEP program, Project PrEPare, from April 2013.
This presentation on New Zealand's approach to HIV prevention was given by Shaun Robinson, Executive Director NZ AIDS Foundation, at the AFAO Members Forum - May 2015.
Electronic cigarettes for smoking cessation: What's the evidence?Health Evidence™
Health Evidence hosted a 90 minute webinar examining the effectiveness of electronic cigarettes for smoking cessation.
Muhannad Malas and Robert Schwartz led the session and presented findings from their recent review:
Malas M, van der Tempel J, Schwartz R, Minichiello A, Lightfoot C, Noormohamed A, et al. (2016). Electronic cigarettes for smoking cessation: A systematic review. Nicotine & Tobacco Research, 18(10), 1926-1936.
http://healthevidence.org/view-article.aspx?a=electronic-cigarettes-smoking-cessation-systematic-review-29830
Cigarette smoking is among the top causes of preventable death and disease. Electronic cigarettes have been increasing in popularity among smokers who report using them for quitting or reducing smoking. This review examines the effectiveness of electronic cigarettes as cessation aids. Sixty two articles, including RCTs, experimental, longitudinal and cross sectional studies are included in this review. Findings suggest there is inconclusive evidence due to low quality of research. This webinar provides a comprehensive overview of current literature examining the effectiveness of electronic cigarettes for smoking cessation.
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Hivlife Info
In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
Format: Microsoft PowerPoint (.ppt)
File size: 825 KB
Date posted: 9/29/2014
This presentation on New Zealand's approach to HIV prevention was given by Shaun Robinson, Executive Director NZ AIDS Foundation, at the AFAO Members Forum - May 2015.
Electronic cigarettes for smoking cessation: What's the evidence?Health Evidence™
Health Evidence hosted a 90 minute webinar examining the effectiveness of electronic cigarettes for smoking cessation.
Muhannad Malas and Robert Schwartz led the session and presented findings from their recent review:
Malas M, van der Tempel J, Schwartz R, Minichiello A, Lightfoot C, Noormohamed A, et al. (2016). Electronic cigarettes for smoking cessation: A systematic review. Nicotine & Tobacco Research, 18(10), 1926-1936.
http://healthevidence.org/view-article.aspx?a=electronic-cigarettes-smoking-cessation-systematic-review-29830
Cigarette smoking is among the top causes of preventable death and disease. Electronic cigarettes have been increasing in popularity among smokers who report using them for quitting or reducing smoking. This review examines the effectiveness of electronic cigarettes as cessation aids. Sixty two articles, including RCTs, experimental, longitudinal and cross sectional studies are included in this review. Findings suggest there is inconclusive evidence due to low quality of research. This webinar provides a comprehensive overview of current literature examining the effectiveness of electronic cigarettes for smoking cessation.
Why, when, and how to use pre exposure prophylaxis for hiv acquisition. 2014Hivlife Info
In this downloadable slide set, Marcy S. Gelman, RN, MSN, MPH, and Kevin M. O’Hara, PA, review essential considerations for midlevel providers administering PrEP
Format: Microsoft PowerPoint (.ppt)
File size: 825 KB
Date posted: 9/29/2014
Before starting his current role as CEO of the St. Hope Foundation in Houston, Robert Goodie served as executive director of the Donald R. Watkins Memorial Foundation. In his work with St. Hope, Robert Goodie oversees several health care delivery and prevention programs focused on chronic and communicable illnesses such as hepatitis C and HIV.
The prophylactic drugs PrEP and PEP have greatly advanced progress towards HIV elimination. PrEP is a daily pill that can reduce the likelihood of developing HIV. PrEP is recommended for people who have an elevated risk of contracting HIV. This includes people with HIV positive partners, people with multiple sexual partners, or people who inject drugs using shared needles.
When taken as recommended and combined with medical monitoring, PrEP can reduce HIV transmission through sex by 99 percent and through intravenous drug use by 70 percent. On the other hand, PEP is a short-term prophylactic intended for people who have been exposed to HIV. PEP is most effective when started less than three days after exposure. A PEP course is prescribed for 28 days.
Views of Australian men who have sex with men on rapid testing for syphilis and HIV. Presentation given by Marcus Chen at the AFAO National Syphilis Forum, 23 October 2009.
Project ECHO (Extension for Community Health Outcomes)icornpresentations
Sanjeev Arora MD, Distinguished Professor of Medicine (Gastroenterology/Hepatology); Director of Project ECHO®
Department of Medicine, University of New Mexico Health Sciences Center
The slide presentation that preceded of the annual Health Datapalooza in Washington DC, PCORI was pleased to participate in the latest installment in the Health Data Consortium and PricewaterhouseCoopers (PwC) Innovators in Health Data Series, a webinar featuring PCORI Executive Director Joe Selby, MD, MPH; NIH Director and PCORI Board of Governors member Francis Collins, MD, PhD; and Philip Bourne, PhD, NIH’s Associate Director for Data Science.
A Decade of Behavioral HIV Prevention and Care Engagement Research in Uganda: Responding to Evolving Epidemic Response Priorities
Susan M. Kiene, PhD, MPH
March 2nd, 2018
UCSD HIV & Global Health Rounds
Kathleen Brady of the PDPH presented the annual report on the HIV epidemic in Philadelphia at the February 2017 meeting of the Philadelphia Ryan White Part A Planning Council.
HPTN 067/ADAPT methods and results from women in Cape TownИлья Антипин
Grant R. и др. «HPTN 067/ADAPT methods and results from women in Cape Town» 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, 2015. MOSY0103.
Project RSP! Training on PrEP for HIV PreventionJim Pickett
This is a training on PrEP (pre-exposure prohylaxis) for HIV prevention, designed for people who work in the HIV prevention field. The training is designed by AIDS Foundation of Chicago's Project Ready, Set, PrEP! (RSP!). For more information on PrEP, visit the project's blog at www.myprepexperience.blogspot.com.
American Thoracic Society (ATS) Annual Meeting 2011
Dr Smita Shah
Director, Primary Health Care Education and Research Unit
Primary Care and Community Health Network
Clinical Senior Lecturer, School of Public Health
Western Clinical School, Poche Centre for Indigenous Health
The University of Sydney, Australia
PrEP training slides - Lisle, April 16, 2015Jim Pickett
These slides are part of a one-day training by Illinois Department of Public Health, Midwest AIDS Training and Education Center, and AIDS Foundation of Chicago (AFC) called "PrEP: What is it and How Am I to Integrate it in My Conversations with Clients?" They were presented by Jim Pickett, Director of Prevention Advocacy and Gay Men's Health at AFC.
TickiT: an eHealth solution to the "Don't Ask, Don't Tell" face to face clini...YTH
The University of British Colombia's Sandy Whitehouse describes the youth friendly mobile platform designed for a clinical setting to help youth communicate issues about their life with their provider. Presented at YTH Live 2014 session "Youth and the Clinical Encounter."
Global Medical Cures™ | HIV TESTING IN USA
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
“Run mummy run” - communicative tensions in digital museum installations that...Areti Galani
Conference presentation for iSay event: The shape of things, University of Leicester, 31 Jan. - 1 Feb. 2013 (http://isayevents.wordpress.com/shapeofthings/).
Before starting his current role as CEO of the St. Hope Foundation in Houston, Robert Goodie served as executive director of the Donald R. Watkins Memorial Foundation. In his work with St. Hope, Robert Goodie oversees several health care delivery and prevention programs focused on chronic and communicable illnesses such as hepatitis C and HIV.
The prophylactic drugs PrEP and PEP have greatly advanced progress towards HIV elimination. PrEP is a daily pill that can reduce the likelihood of developing HIV. PrEP is recommended for people who have an elevated risk of contracting HIV. This includes people with HIV positive partners, people with multiple sexual partners, or people who inject drugs using shared needles.
When taken as recommended and combined with medical monitoring, PrEP can reduce HIV transmission through sex by 99 percent and through intravenous drug use by 70 percent. On the other hand, PEP is a short-term prophylactic intended for people who have been exposed to HIV. PEP is most effective when started less than three days after exposure. A PEP course is prescribed for 28 days.
Views of Australian men who have sex with men on rapid testing for syphilis and HIV. Presentation given by Marcus Chen at the AFAO National Syphilis Forum, 23 October 2009.
Project ECHO (Extension for Community Health Outcomes)icornpresentations
Sanjeev Arora MD, Distinguished Professor of Medicine (Gastroenterology/Hepatology); Director of Project ECHO®
Department of Medicine, University of New Mexico Health Sciences Center
The slide presentation that preceded of the annual Health Datapalooza in Washington DC, PCORI was pleased to participate in the latest installment in the Health Data Consortium and PricewaterhouseCoopers (PwC) Innovators in Health Data Series, a webinar featuring PCORI Executive Director Joe Selby, MD, MPH; NIH Director and PCORI Board of Governors member Francis Collins, MD, PhD; and Philip Bourne, PhD, NIH’s Associate Director for Data Science.
A Decade of Behavioral HIV Prevention and Care Engagement Research in Uganda: Responding to Evolving Epidemic Response Priorities
Susan M. Kiene, PhD, MPH
March 2nd, 2018
UCSD HIV & Global Health Rounds
Kathleen Brady of the PDPH presented the annual report on the HIV epidemic in Philadelphia at the February 2017 meeting of the Philadelphia Ryan White Part A Planning Council.
HPTN 067/ADAPT methods and results from women in Cape TownИлья Антипин
Grant R. и др. «HPTN 067/ADAPT methods and results from women in Cape Town» 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, 2015. MOSY0103.
Project RSP! Training on PrEP for HIV PreventionJim Pickett
This is a training on PrEP (pre-exposure prohylaxis) for HIV prevention, designed for people who work in the HIV prevention field. The training is designed by AIDS Foundation of Chicago's Project Ready, Set, PrEP! (RSP!). For more information on PrEP, visit the project's blog at www.myprepexperience.blogspot.com.
American Thoracic Society (ATS) Annual Meeting 2011
Dr Smita Shah
Director, Primary Health Care Education and Research Unit
Primary Care and Community Health Network
Clinical Senior Lecturer, School of Public Health
Western Clinical School, Poche Centre for Indigenous Health
The University of Sydney, Australia
PrEP training slides - Lisle, April 16, 2015Jim Pickett
These slides are part of a one-day training by Illinois Department of Public Health, Midwest AIDS Training and Education Center, and AIDS Foundation of Chicago (AFC) called "PrEP: What is it and How Am I to Integrate it in My Conversations with Clients?" They were presented by Jim Pickett, Director of Prevention Advocacy and Gay Men's Health at AFC.
TickiT: an eHealth solution to the "Don't Ask, Don't Tell" face to face clini...YTH
The University of British Colombia's Sandy Whitehouse describes the youth friendly mobile platform designed for a clinical setting to help youth communicate issues about their life with their provider. Presented at YTH Live 2014 session "Youth and the Clinical Encounter."
Global Medical Cures™ | HIV TESTING IN USA
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
“Run mummy run” - communicative tensions in digital museum installations that...Areti Galani
Conference presentation for iSay event: The shape of things, University of Leicester, 31 Jan. - 1 Feb. 2013 (http://isayevents.wordpress.com/shapeofthings/).
Discussion on the Facebook's initiative Facebook for Non-Profits. Why Facebook has launched this facility for Non-Profits. What are the for and against of the same. Why we can look forward for this.
Technical Writing. Why to opt for Technical Writing as a career. Salary and expectations from this profession. Why one should get certified before entering as a technical writer.
10 eventowych trendów na 2017 rok #CeluchConsulting 1. wzrost roli miast "drugiego wyboru" 2. żyć jak mieszkańcy 3. unikatowe miejsca 4. zaangażowanie 5. kulinarna przygoda 6. uczestnicy młodzi/ alumni 7. osobiste doświadczenia 8. ekonomia współdzielenia 9. bezpieczeństwo 10. kapitał intelektualny
Project RSP! Training on PrEP for HIV PreventionJim Pickett
June 11 - UPDATED training on PrEP for HIV prevention from Chicago's Project Ready, Set, PrEP! (RSP!). Visit the Project RSP!'s My PrEP Experience blog at www.myprepexperience.blogspot.com for more informational resources, including the personal stories of individuals who have chosen to use PrEP.
Project Ready, Set, PrEP! training on PrEP for HIV Prevention - UPDATED NOV 17Jim Pickett
This training on PrEP for HIV prevention was conducted by AIDS Foundation of Chicago (AFC) in collaboration with the Chicago Department of Public Health on November 17. Other partners on this training included University of Chicago. These slides comprise a 3.5 hour training designed for people in the HIV workforce that AFC and partners conduct at various times in the year. They are continually updated.
Project Ready, Set, PrEP! training on PrEP - Updated 9/5/14Jim Pickett
This training on PrEP for HIV prevention was conducted by AIDS Foundation of Chicago (AFC) in collaboration with the Chicago Department of Public Health and MATEC on September 5, 2014. Other partners on this training included John Stroger Hospital and Gilead. These slides comprise a 3.5 hour training designed for people in the HIV workforce AFC and partners conduct at various times in the year.
Dr. Kathleen Brady's presentation on PrEP (pre-exposure prophylaxis) for HIV, as given to the Philadelphia HIV Prevention Planning Group (HPG) on March 25, 2015.
Jill Blumenthal, MD
Assistant Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
Project RSP! training on PrEP - updated November 2013Jim Pickett
This is a training for the HIV workforce on PrEP, and is a part of Chicago's Project Ready, Set, PrEP! (RSP!) Project RSP! is an education and awareness initiative of the AIDS Foundation of Chicago. Visit us at www.myprepexperience.blogspot.com.
Into the Vast Unknown: Early Lessons from a PrEP Demonstration Project in Cis-gender Women in Southern California
Jill Blumenthal MD
August 25th, 2017
UCSD HIV & Global Health Rounds
PrEP Training Slides - Austin CBC, CORE Center, AFCJim Pickett
These slides were used for the HIV workforce PrEP training conducted by AIDS Foundation of Chicago on June 23, 2015 at Austin CBC in collaboration with the CORE Center.
Современное лечение ВИЧ : АРТ как профилактика.Contemporary Management of HIV...hivlifeinfo
Contemporary Management of HIV. Antiretroviral Therapy As Prevention.2016
In this downloadable slideset, Kenneth Mayer, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for pre- and post-exposure prophylaxis in patients at risk for HIV infection.
Format: Microsoft PowerPoint (.ppt)
File size: 2.13 MB
CHAMP Monthly Teleconference Training - PrEP's the Word: Everyone's Talking About It... But What Do We Need To Know, And Do, About Pre-Exposure Prophylaxis
Project RSP! Training on PrEP - Oct 2013Jim Pickett
This training was conducted for members of the HIV workforce in Chicago on October 21, 2013 at the Chicago Department of Public Health's Mile Square location.
Similar to Project PrEPare - presented by Dr. Sarah Wood and Kimberley Desir (20)
Overview of the 2018 Update to the Integrated Plan and PrEP Workgroup Draft R...Office of HIV Planning
Mari Ross-Russell (Office of HIV Planning) and Matthew McClain (Public Health Policy & Planning Consultant) presented these slides to the PrEP Workgroup of the Philadelphia EMA HIV Integrated Planning Council on January 16, 2019.
Dr. William R. Short presented this review of PrEP research from the Conference on Retroviruses and Opportunistic Infections to the PrEP Workgroup of the HIPC's Prevention Committee in April 2018.
Sebastian Branca of the AIDS Activities Coordinating Office provided this overview of AACO's quality management program to the HIV Integrated Planning Council on May 10, 2018. This presentation includes discussion of secret shoppers, quality improvement plans, and quality management initiatives.
C-YA! Philadelphia EMA's Plan to Connect our Co-infected Community to a Cure ...Office of HIV Planning
Alex Shirreffs of the Philadelphia Department of Public Health provided this overview of the Philadelphia area's plan to end HIV and Hepatitis C coinfections to the HIV Integrated Planning Council on May 10, 2018.
Ricardo Colon of the AIDS Activities Coordinating Office provided this overview of AACO's Client Services Unit to the HIV Integrated Planning Council on May 10, 2018. It includes information on the medical case management program and top needs identified at client intake.
This presentation was provided to the Philadelphia EMA HIV Integrated Planning Council by Briana Morgan of the Office of HIV Planning. It includes data related to population-level data, race/ethnicity, STIs, risk behaviors, HIV, and more.
Dr. Kathleen Brady of the AIDS Activities Coordinating Office presented this epidemiologic update to the Philadelphia EMA HIV Integrated Planning Council on February 9, 2018.
Increasing Treatment Access and Saving Lives in the Dual Opioid and Overdose ...Office of HIV Planning
Silvana Mazzella of Prevention Point Philadelphia gave this presentation on medication assisted treatment to the Philadelphia EMA HIV Integrated Planning Council on March 8, 2018.
Dr. Kathleen Brady of the AIDS Activities Coordinating Office discussed three cycles of the National HIV Behavioral Surveillance in Philadelphia, including cycles with men who have sex with men (MSM), high-risk heterosexuals, and injection drug users. This presentation took place at the Philadelphia EMA HIV Integrated Planning Council meeting on Thursday, January 11, 2018.
Caitlin Conyngham and Erika Aaron of the AIDS Activities Coordinating Office began the initial meeting of the PrEP Working Group with this presentation on November 15, 2017.
Antonio Boone of the Office of HIV Planning reviewed major points from the Mayor's Task Force to Combat the Opioid Epidemic in Philadelphia at the June 12, 2017 Positive Committee meeting.
Marcy Witherspoon, MSW, LSW of the Health Federation of Philadelphia discussed trauma-informed care with the Philadelphia EMA HIV Integrated Planning Council on November 9, 2018.
OHP's Antonio Boone gave this presentation on different prevention continuum examples at the July meeting of the Prevention Committee of the Philadelphia EMA HIV Integrated Planning Council.
Integrated HIV Surveillance and Prevention Programs for Health Departments - ...Office of HIV Planning
Caitlin Conyngham, Prevention Coordinator at the AIDS Activities Coordinating Office at the Philadelphia Department of Public Health, gave an overview of the new HIV prevention notice of funding opportunity to the HIPC's Prevention Committee on 07-26-2017.
Opioid Awareness - Report Review: The Mayor's Task Force to Combat the Opioid...Office of HIV Planning
The OHP's Antonio Boone presented at the June 2017 meeting of the Positive Committee on the recent report from the Mayor's Task Force to Combat the Opioid Epidemic in Philadelphia.
Planning Council Co-Chair and Prevention Committee member Jen Chapman presented on integrated planning and concurrence at the May 2017 meeting of the HIV Integrated Planning Council.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Hemodialysis: Chapter 3, Dialysis Water Unit - Dr.Gawad
Project PrEPare - presented by Dr. Sarah Wood and Kimberley Desir
1.
2. CHOP Project PrEPare Team
Study Coordinator: Alison Lin MPH,
lina1@email.chop.edu
Physician: Sarah Wood MD,
woodsa@email.chop.edu
Research Nurse: Courtney Rooney
RN, rooneyc@email.chop.edu
Research Assistant: Kimberley Desir
BA, DesirK@email.chop.edu
3. Overview
What is PrEP ?
Why PrEP Matters
The Science of PrEP
Making Prevention Choices
How To Get PrEPared
Project PrEPare at CHOP
Risks and Benefits
4. What Is PrEP?
Pre-exposure prophylaxis (PrEP) is
antiretroviral medicine taken daily
by HIV-negative people to reduce
their risk of infection
5. Truvada-based PrEP
Truvada is a combination of 2 drugs: tenofovir and
emtricitabine
Used as HIV treatment since 2004
Approved for PrEP in 2012 as part of a
comprehensive HIV prevention plan
14. How well does it work?
TRIAL Pop n= Intervention Overall
efficacy
Efficacy
with
maximal
adherence
iPrEx MSM 2499 Truvada v placebo 42% 92%
Partners
PrEP
Serodisc.
Couples
~4700
couples
Truvada v TDF
alone vs placebo
75% 90%
TDF2 Heterosex
M & F
1219 Truvada v placebo 63% 78%
Fem PrEP Women 18-
35
1951 Truvada v placebo Stopped
by DSMB
VOICE Women 5028 Oral TDF vs vaginal
gel vs Truvada vs
placebo
Not
effective
Too low to
determine
15. For PrEP to work you have to
take it every day
All of the PrEP studies have
shown the greatest HIV risk
reduction among the most
adherent participants
Adherence Matters
16. What are the Risks of PrEP?
•Truvada is generally safe and well tolerated
•Minor side effects can occur including nausea,
vomiting, diarrhea, and dizziness.
•Most side effects get better within 1-2 months
•No evidence of resistance to Truvada in trials
•Serious side effects
•Changes in bone mineral density
•Kidney disease
17. Some people are concerned
that people who use PrEP will
have a false sense of
protection and may engage in
risky sexual behaviors because
of it
What are Risks of PrEP?
18. But, doing more risky things
hasn’t been the case for:
•youth when condoms were made
widely available in schools;
• youth when birth control has been
provided; or
•adults in any of the previous PrEP
trials
•In prior PrEP trials, risk behaviors
actually decreased
19. Making Prevention Choices
Things to consider in making the decision
Can you remember to take a pill every day?
Do you have any history of bone or kidney problems?
Do you have people in your life who will support you
taking PrEP?
Do you have a health care provider you can talk to
about PrEP?
20. Where is PrEP available?
Your primary doctor
Infectious diseases specialists
Clinical trials
21. Current PrEP Studies
There are over 21,000 people world wide who are helping
us end the HIV epidemic by enrolling in PrEP studies
22. Project PrEPare Study Objectives
Adolescent Trials Network Protocol 110
Study Goals
• To get more information about safety of Truvada®
• To evaluate how well YMSM take PrEP and if there risk
behavior changes
• To explore how well risk reduction interventions work as
part of PrEP programs
23. Project PrEPare: Study PopulationApproximately 200
HIV-uninfected
YMSM ages 18-22 at
high risk of acquiring
HIV infection
Trans women
included
Philadelphia will
recruit 25 youth
24. What is involved for participants?
The trial is 1-2 years long
Prescreening is in person or online
Monthly study visits for the first 4 months. The
remaining visits will be every 3 months
All participants get daily Truvada
Each study visit involves comprehensive HIV
prevention care: physical exam, blood and urine tests,
risk reduction counseling
HIV testing every month
DEXA (bone density) scanning throughout
the study.
25. What is involved for participants?
Behavioral Interventions
Personalized Cognitive Counseling (PCC)
Integrated Next Step Counseling (iNSC):
Text messaging daily reminders for adherence
28. What are the benefits of
enrollment?
Studies have shown that PrEP reduces the risk of HIV
infection in MSM especially in those most adherent to
the medications
Participants may benefit from receiving the behavioral
risk reduction counseling
29. Why Join a PrEP Clinical Trial?
Access to extra support for adherence and risk
reduction
Close monitoring
Help the community learn more about ways to stop
the HIV epidemic
Make sure that youth are represented in what we
know about PrEP
30. To Learn More About PrEP:
Project PrEPare Website: www.projectprepare.net
Centers for Disease Control and Prevention:
www.cdc.gov/msm/prep
Project inform:
http://www.projectinform.org/pdf/prep_msm.pdf
www.prepfacts.org
PrEP watch: http://www.prepwatch.org/#guidance
SW To reduce the risk of sexually-acquired HIV infection in high risk adults, as part of a comprehensive HIV prevention planthat includes consistent and correct condom use, risk reduction counseling, regular HIV testing, and treatment of any other sexually-transmitted infections.” (FDA Consumer Health Information, July 2012)
KD
KD
So why do we need PrEP? Why can’t everyone just use condoms?
SW Young MSM were underrepresented in prior PrEP trials.
Youth ages 13-29 years accounted for 39% of new HIV infections in 2009 in the U.S.
Over two-thirds of all new youth infections occurred in MSM
MSM aged 13–24 had the greatest percentage increase (44%) in diagnoses of HIV infection from 2007 through 2010 and exceeded the number of diagnoses among those aged 35–44 by 2010.
SWIn the U.S., youth ages 13-29 years accounted for 39% of new HIV infections in 2009.
Over two-thirds (69%) of all new youth infections occurred in MSM and among young black MSM, and new HIV infections increased 48% from 2006 - 2009.
Among all MSM, Hispanic/Latino MSM accounted for 6,000 (20%) new HIV infections in 2009. The largest percentage of new infections (45%) occurred in those aged 13–29
SW
SW Truvada works by blocking reverse transcriptase—the protein that lets HIV make copies of itself. If the virus can’t copy itself, it dies and the “host” never gets infected.
SW Partners PrEP: TDF vs Truvada vs placebo iPrEx Study: 2,499 MSM got Truvada or placebo
PrEP arm reduced their risk of HIV infection by 44%.
Those that took PrEP consistently enough that the medicine could be measured in their blood, reduced their risk of HIV infection by 92%.
Partners PrEP: 4,700 serodiscordant couples in Africa
Truvada group reduced their risk for HIV infection by 75%
Those that took PrEP consistently enough that the medicine could be measured in their blood, reduced their risk of HIV infection by 90%.
CDC TDF2 Study: 1200 young men and women in Botswana
Truvada reduced their risk for HIV infection by 63%
There was a 78% risk reduction when excluding participants who had not refilled their medication for >30 days
SW 44 vs 92% is a Big Difference
SW The CDC recommends visits at least every 2-3 months to assess for side effects, test for HIV and STI’s and monitor adherence.
In prior PrEP studies, changes in kidney blood test results were very rare, and resolved when participants stopped taking the drugs.
Researchers also measured participants’ bone density while on Truvada and found that these medications did cause a slight reduction in bone thickness, but not an increase in fractures.
KD youth when condoms were made widely available in schools;
youth when birth control has been provided; or
adults in any of the previous PrEP trials
In prior PrEP trials, risk behaviors actually decreased
KD
KD
SW
Clin trials help us learn more about HIV and how to stop the epidemic
January, 2011: CDC issued guidelines for PrEP use in high-risk MSMs
PrEP to be used as part of comprehensive set of prevention services, including condoms, risk-reduction, adherence counseling, STI diagnosis and treatment
Should be part of a plan of care with regular HIV testing, adherence counseling and monitoring of side effects (every 2-3 months).
August 2012: Similar guidelines published for high risk heterosexual adults.
SW
SW
Project PrEPare is an innovative HIV prevention study designed to explore the safety, acceptability and feasibility of PrEP among young men who have sex with men (YMSM) who are at risk for HIV infection in the United States. This study will take place at 14 clinical sites across the U.S. with about 200 HIV-uninfected YMSM, ages 18-22.
What is Project PrEPare?
Project PrEPare is a comprehensive HIV prevention study designed to obtain additional data on the safety and efficacy of FTC/TDF and to evaluate patterns of use, rates of adherence, and patterns of sexual risk behavior among YMSM who are provided with FTC/TDF help to determine if PrEP could become a part of a comprehensive HIV prevention package for YMSM in the real world. All participants will complete one of two proven behavioral HIV-prevention interventions offered at their local sites, be provided ongoing counseling, regular HIV/STI testing, and medical follow-up along with a daily dose of PrEP (FTC/TDF).
KD
Where will Project PrEPare take place?
Project PrEPare will take place at 14 clinical sites across the United States. Study sites can be found in Tampa, Los Angeles, Washington DC, Philadelphia, Chicago, Bronx, New Orleans, Miami, Memphis, Houston, Detroit, Baltimore, Boston and Denver. Site specific contact information can be found on the Project PrEPare website – www.projectprepare.net
No history of significant bone or kidney disease
Planning to stay in the area for at least 1 year
When will Project PrEPare begin, and how long will it last?
Project PrEPare is expected begin enrollment in the fall of 2012 and every participant will be followed for at least 48 weeks but could be followed up to 120 weeks. Participants will visit the study clinics at four, eight and 12 weeks, and every 12 weeks thereafter.
t risk” criteria
KD
HIV testing at each visit, counseling at each visit
KD All participants receive intensive risk-reduction intervention to reduce HIV-related risk behavior
In a randomized controlled trial of PCC, Dilley and colleagues found that men receiving the PCC intervention had a significant decrease in percent (p < 0.002 and p = 0.001, respectively) and in mean number of episodes (p < 0.008 and p < 0.001, respectively) of unprotected anal sex, compared to those receiving standard HIV counseling, at both the 6 and 12-month follow-up points (Dilley, et al., 2002).
KD $dexa weeks is $75, other weeks are $50. If eligible and refuse but do PrEP survey: get gift card. Tokens provided for all visits
KD
KD PCC, condoms, STD screening and treatment, referrals for hepatitis B vaccination as needed, and periodic HIV testing and counseling)